Detalles de la búsqueda
1.
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
N Engl J Med
; 388(7): 595-608, 2023 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36791160
2.
Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions.
Clin Infect Dis
; 78(1): 202-209, 2024 01 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37698366
3.
Efficacy and safety of respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons.
Clin Infect Dis
; 2024 Jan 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38253338
4.
The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age.
Influenza Other Respir Viruses
; 18(2): e13236, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38314063
5.
Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.
Vaccine
; 39(11): 1598-1608, 2021 03 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33612341
6.
Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial.
Vaccine
; 38(8): 2105-2114, 2020 02 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-31776027
7.
Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial.
Vaccine
; 38(8): 2095-2104, 2020 02 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-31776029
8.
Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
Vaccine
; 36(42): 6325-6333, 2018 10 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30197282
9.
Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
Hum Vaccin Immunother
; 14(8): 1977-1986, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29630439
10.
Corrigendum to 'Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults'. [Vaccine 36 (2018) 6325-6333].
Vaccine
; 38(12): 2746-2747, 2020 Mar 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32061383
Resultados
1 -
10
de 10
1
Próxima >
>>